AMRX Q4 2025 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q4 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$814M+11.5% YoY

Gross Profit

$297M36.5% margin

Operating Income

$115M14.1% margin

Net Income

$35M4.3% margin

EPS (Diluted)

$0.11

QoQ Revenue Growth

+3.8%

Cash Flow

Operating Cash Flow

$130M

Free Cash Flow

$87M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$3.7B

Total Liabilities

$3.7B

Stockholders' Equity

-$71M

Cash & Equivalents

$311M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$814M	$731M	+11.5%
Gross Profit	$297M	$263M	+13.1%
Operating Income	$115M	$76M	+51.1%
Net Income	$35M	-$31M	+212.9%

Revenue Segments

Specialty Segment

$420M100%

Geographic Segments

Specialty Segment

$275M100%